In March this year, CellGENTherapies has announced their one full floor new GMP facility in the Nobel Building on Ghent University campus. This initiative is being funded by EFRO, FWO and the Ghent University Hospital. The team has worked hard to review the design plans of the cutting-edge cleanrooms with a focus on optimal processing…

Ghent University Hospital and its GMP facility CellGENTherapies, are partner in an ambitious, international (ATTRACT) study, called ARI-chALL, to investigate whether an innovative, academically developed CAR-T cell therapy can be used in children with acute lymphoblastic leukaemia during their first relapse. The new ARI-chALL study – which will take place in Belgium (Ghent), Spain, the…

Ghent University and CellGENTherapies, the GMP facility of Ghent University hospital, are key partner in ATMP XB, a cross-border initiative between Flanders and the Netherlands. The aim is to accelerate the development, production, and quality control of Advanced Therapy Medicinal Products (ATMPs). ATMP XB includes: The goal is a learning network to address process development…

CellGENTherapies is attracted by the VIB and the Katholieke Universiteit Leuven (Prof Dieter Lambrechts) to produce a lipid nanoparticle RNA cancer vaccine using the Galsome technology developed by Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt and Dr Ine Lentacker) for a clinical trial in patients with hepatocellular carcinoma (PI prof Jeroen Dekervel, UZLeuven).…

Prof Bart Vandekerckhove, head of the GMP unit ‘CellGENTherapies’ of Ugent and UZ Gent, has received an important grant of €790K from ‘the Stichting Tegen Kanker (STK)’ and ‘Kom op tegen Kanker (KOTK)’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of…

On the UZ Gent campus, a new GMP unit is being built, covering no less than 1000 m2 and meeting the latest quality requirements. The new GMP unit will be fully operational by the end of 2026. With the new facilities, the University Hospital of Ghent (UZ Gent) continues to facilitate research into innovative applications…

The City of Ghent supports future-oriented economic clusters, focusing on the present spearheads biotech & life sciences, cleantech, healthtech and digitech, in their further growth. For the further development of these ecosystems, both locally and internationally, the City of Ghent has established a spearhead fund of €4.9 million. The GMP facility ‘CellGENTherapies’ at University hospital…

Headed by prof. Bart Vandekerckhove, in 2024 “CellGENTherapies”, the GMP unit of University Hospital of Ghent (UZ Gent) and the University of Ghent (Ugent), has received €4.6 million external funding from Europees Fonds voor Regionale Ontwikkeling (EFRO RNAvance), Fonds voor Innoveren en Ondernemen (FIO) and Fonds voor Wetenschappelijk Onderzoek (FWO-Hercules). This budget supplemented with an…